Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000670287 | SCV000795121 | uncertain significance | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-10-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001300493 | SCV001489636 | pathogenic | not provided | 2023-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 466 of the USH2A protein (p.Gly466Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with retinitis pigmentosa (PMID: 24938718, 31960602; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 554616). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003459614 | SCV004206325 | pathogenic | Retinitis pigmentosa 39 | 2023-02-16 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001829863 | SCV002093987 | uncertain significance | Usher syndrome type 2A | 2020-07-27 | no assertion criteria provided | clinical testing |